AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 51 min read$EDIT

O'Neill Gilmore Neil sold $42K of EDIT

O'Neill Gilmore Neil (CEO) sold 15,380 shares of Editas Medicine, Inc. (EDIT) at $2.70 on 2026-06-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · O'Neill Gilmore Neil
Published Jun 5, 2026, 8:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 5, 2026, 8:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$EDIT
Neutral
medium confidence
Mentioned
$EDIT
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EDITNeutralLow
01

Why it matters

The disclosure may cause short-term sentiment noise, but it does not provide new information about Editas’ pipeline, trial results, financing, or regulatory status.

02

Market read

Traders may monitor for follow-on insider activity, but the 10b5-1 framing limits fundamental inference.

03

What to watch

The article doesn’t state total planned volume, prior sale cadence, or whether proceeds relate to tax/portfolio needs—those details can change interpretation.

Relevance 6/10Novelty 3/10Timing: SEC Form 4 filed June 5 (sale executed June 3)

Background

This is an SEC Form 4 insider transaction: an officer/director reports an open-market sale executed under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$EDITNeutralMedium confidence
Context

Editas Medicine CEO sold 15,380 shares in an open-market transaction disclosed via SEC Form 4 on June 3 under a 10b5-1 plan.

Expected impact

Low likelihood of sustained price impact; any reaction is likely brief unless accompanied by other company-specific news.

Evidence & confidence

The filing provides a disclosed sale size and price, but no new operational/clinical/regulatory catalyst; 10b5-1 typically reduces interpretive weight.

Market effects

Sector

Small read-through for biotech insider sentiment, but no direct sector catalyst is introduced.

Regional

None indicated; US-listed biotech-specific disclosure only.

Global

None indicated; single-company insider transaction.

Counterpoint

What could challenge this read

Even with a 10b5-1 plan, repeated or larger-than-usual sales can still coincide with management confidence gaps; traders may still fade strength if selling is persistent.

Key entities

  • issuer
    Editas Medicine, Inc.

    Subject of the Form 4 insider sale by CEO O'Neill Gilmore Neil.

  • insider
    O'Neill Gilmore Neil

    CEO and officer/director who sold 15,380 shares at $2.7011 on June 3 under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

EDIT insider trading history →

Related articles

OCT 28
$PRMEHighAI 8/10

PRME, BEAM, EDIT, NTLA, CRSP Stocks Gain As FDA Signals Faster Route For Patient-Specific Gene Edits

Shares of gene-editing companies, including Prime Medicine (PRME), Beam Therapeutics, Intellia Therapeutics (NTLA), Editas Medicine (EDIT), and CRISPR Therapeutics (CRSP), rose after the FDA issued draft guidance to expedite personalized treatments for rare genetic diseases. The new approach allows one application for multiple versions of the same gene-editing treatment. PRME gained 20%, with other companies seeing 4-14% increases.

stocktwits.com2 min
OCT 9
$EDITMedAI 8/10

EDIT Set to Begin First-in-Human Study in Hypercholesterolemia

Editas Medicine received approval to begin a phase I/II study for EDIT-401, a gene-editing therapy for heterozygous familial hypercholesterolemia, in Australia. The study aims to evaluate safety, tolerability, and efficacy, with dosing expected to start in 2026. EDIT-401 targets LDL cholesterol through gene editing, potentially offering long-lasting reductions. The company's stock has risen 38.5% year-to-date, outperforming the industry.

zacks.com2 min
OCT 8
$EDITMedAI 8/10

Wells Fargo Upgrades Editas Medicine (EDIT) on Phase 1/2 Trial A

Wells Fargo upgraded Editas Medicine (EDIT) to Overweight, raising its price target to $6 from $4. This follows the company's approval to start a Phase 1/2 trial for EDIT-401 in Australia, targeting a genetic condition. Editas has a P/S ratio of 6.15, below its historical median of 33.7x, and a GF Score of 51/100, indicating moderate fundamentals with weak profitability and financial strength.

gurufocus.com2 min